secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK:        0001430306
Form:       8-K
Filed at:   2025-07-10T23:59:59+00:00
Accession:  0001999371-25-008900
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tonix TNX-801 vaccine data: 100,000-fold less virulent, s.c. route protective
-----------------------------------------------------------------------------

- TNX-801 is up to 100,000-fold less virulent than licensed vaccinia in interferon receptor knockout mice.
- Subcutaneous administration yields equivalent protection to percutaneous route; company plans s.c. product first.
- Single dose protected all vaccinated macaques from lethal Clade I mpox challenge without lesions.
- Rabbit models remained fully protected for 14 months post single dose.
- Company to advance TNX-801 into clinic via subcutaneous delivery for mpox and smallpox prevention.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1430306/000199937125008900/0001999371-25-008900-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1430306/000199937125008900/tonix-8k_071025.htm
  HTML page:      https://secwatch.observer/filing/0001999371-25-008900

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer